| Literature DB >> 33554067 |
Jonghun Kim1, Gareth J Sullivan2, In-Hyun Park1.
Abstract
Brain organoids closely recapitulate many features and characteristics of in vivo brain tissue. This technology in turn allows unprecedented possibilities to investigate brain development and function in the dish. Several brain organoid protocols have been established, and the studies have focused on validating the architecture, cellular composition, and function of the organoids. In future, the improved and advanced organoid models will enable us to understand cellular and molecular features of the developing brain. However, several obstacles, such as the quality of the organoids, 3D structural analysis, and measurement of the neural connectivity need to be improved. In this perspective, we will provide an overview of the current state of the art of the brain organoid field, with a focus on protocols and organoid characterization. Additionally, we will address the current limitations of this evolving field and provide an understanding of the current brain organoid landscape and insight toward the next steps.Entities:
Keywords: neuroscience; tissue engineering
Year: 2021 PMID: 33554067 PMCID: PMC7856464 DOI: 10.1016/j.isci.2021.102063
Source DB: PubMed Journal: iScience ISSN: 2589-0042
Overview of current brain organoid protocols
| Methodology | Regional identity | Type of organoid | Extrinsic factors | Assessment | Reference |
|---|---|---|---|---|---|
| Unguided method | Whole brain | Cerebral organoid | - | Immunostaining | ( |
| Whole brain | Cerebral organoid | - | Immunostaining | ( | |
| Forebrain | Microfilament-engineered cerebral organoid | CHIR99021 (pulse) | Immunostaining | ( | |
| Transplanted cerebral organoid | - | Immunostaining | ( | ||
| Air-liquid interface cerebral organoid | CHIR99021 (pulse) | Immunostaining | ( | ||
| Guided method | Cerebral cortex | Cortical tissue | Dkk-1, Lefty-A, and BMPRIA-Fc | Immunostaining | ( |
| Cortical neuroepithelium | IWR1e and SB431542 | Immunostaining | ( | ||
| Cortical spheroid | Dorsomorphin and SB431542 | Immunostaining | ( | ||
| Cortical organoid | Noggin and rhDkk1 | Immunostaining | ( | ||
| Forebrain organoid | Dorsomorphin, A83-01, WNT-3A, CHIR99021, and SB431542 | Immunostaining | ( | ||
| Cortical organoid | SB431542, LDN193189, and XAV939 | Immunostaining | ( | ||
| Cortical spheroid | Dorsomorphin and SB431542 | Immunostaining | ( | ||
| Forebrain organoid | IWR1e and SB431542 | Immunostaining | ( | ||
| Ventral forebrain | Subpallium spheroid | Dorsomorphin, SB431542, | Immunostaining | ( | |
| Ventral organoid | Immunostaining | ( | |||
| Ventral forebrain organoid | Noggin, SB431542, CHIR99021, | Immunostaining | ( | ||
| Medial ganglionic eminence | MGE organoid | SB431542, LDN193189, and XAV939, | Immunostaining | ( | |
| Thalamus | Thalamus organoid | SB431542, LDN193189, Insulin, | Immunostaining | ( | |
| Hypothalamus | Hypothalamus organoid | SB431542, LDN193189, | Immunostaining | ( | |
| Midbrain | Midbrain organoid | SB431542, Noggin, CHIR99021, | Immunostaining | ( | |
| Midbrain organoid | SB431542, LDN193189, CHIR99021, | Immunostaining | ( | ||
| Cerebellum | Cerebellar tissue | SB431542, Insulin, FGF2, | Immunostaining | ( | |
| Hippocampus | Hippocampal tissue | SB431542, IWR1e, | Immunostaining | ( | |
| Choroid plexus | Choroid plexus tissue | SB431542, IWR1e, | Immunostaining | ( | |
| Choroid plexus organoid | Immunostaining | ( | |||
| Spinal cord | Neuromuscular organoid | Immunostaining | ( |
Patterning factors.
Figure 1Methods to generate and analyze brain organoids
Unguided methods that do not use specific chemicals or inhibitors produce cerebral organoids with a high cellular diversity but with higher heterogeneity. Guided methods use signaling activators or inhibitors to produce region-specific brain organoids. Architecture, cellular diversity, and function of the brain organoids are assayed by multiple methods.
Figure 2Patterning and morphogens in the neural tube
In the fetal brain, the dorsoventral and anteroposterior (rostrocaudal) developmental fate of the primary vesicles are determined by the morphogens. Following the default neuroectoderm commitment by inhibition of BMP signaling, the WNT and SHH signals determine the dorsoventral axis, and FGF8 signal determines the rostrocaudal fate. The combination of the agonists and antagonists of these signaling pathways is used to generate the regionally defined brain organoids in Figure 1.
Figure 3Future perspectives in brain organoids
Developing brain organoids with structurally better organized, reproducing the CNS-PNS connection, and physiological environment is needed. The improved brain organoids system will be critical to model human brain development and brain disorders, and to perform drug discovery and personalized therapeutics.